Stock data
Actuate Therapeutics, Inc. (ACTU)
Actuate Therapeutics, Inc. (ACTU) reported net income of -US$22.23M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$22.50M | -US$22.23M | — |
| 2024 | — | — | -US$25.16M | -US$27.29M | — |
| 2023 | — | — | -US$24.97M | -US$24.74M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$4.87M | — |
| 2026-03-31 | — | -US$5.63M | — |
| 2025-12-31 | — | -US$4.55M | — |
| 2025-09-30 | — | -US$5.41M | — |
| 2025-06-30 | — | -US$5.95M | — |
| 2025-03-31 | — | -US$6.32M | — |
| 2024-12-31 | — | -US$6.45M | — |
| 2024-09-30 | — | -US$5.97M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.